Condition Directory

Obesity clinical trials

Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5498

Shown on this page

Current sort

How Obesity studies are organized in the registry

Obesity research spreads across several neighboring registry terms — “overweight,” “weight loss,” and “metabolic syndrome” all label closely related studies — so checking more than one term gives a fuller picture. The portfolio includes many behavioral and lifestyle studies alongside drug trials, which makes the study-type filter (interventional vs. observational) more informative than usual.

Terms that often appear in related listings

weight loss overweight metabolic syndrome bariatric

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 5,498 matching trials for Obesity.

Live ClinicalTrials.gov results.

Active filters: "overweight" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Obesity, Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteer, Obestity
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Columbus, Ohio

Conditions: Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Interventions: ALN-4324, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Electric Stimulation Therapy, Obesity, Weight Loss, Eating
Interventions: Transcranial Direct Current Stimulation (TDCS), Sham/no-stimulation; Device · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Obesity, Diet Therapy, Weight Loss, Weight Gain, Nutrition Therapy
Interventions: Weight Loss, Overfeeding, Overfeeding Low Pro; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Insulin Resistance, Obesity
Interventions: Alpha-lipoic acid, Mirabegron, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, Knee
Interventions: Diet and Exercise; Behavioral
Lead sponsor: Wake Forest University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 1,230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Obesity Type 2 Diabetes Mellitus, Obesity (Disorder)
Interventions: GLP-1 Therapy; Drug
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Columbia, South Carolina • Greenville, South Carolina

Conditions: Healthy Participants
Interventions: Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Obesity, Diabetes
Interventions: Quercetin, Placebo; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pseudohypoparathyroidism Type 1a, Obesity
Interventions: Setmelanotide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

About this Obesity clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Obesity clinical trials

How Obesity studies are organized in the registry

Filter and sort this condition

Live official records

Physical and Behavioral Traits of Overweight and Obese Adults

Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

The Osteoarthritis Prevention Study

Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

About this Obesity clinical trials directory page